Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
The aim of this study is to test the hypothesis that canakinumab treatments will prevent recurrent cardiovascular events. This study will include blood draws, physical exams, vital signs, urine collection, EKGs and study drug dispensing. All study related testing will be completed at no cost to the patient. Compensation may occur for qualified patients.
- Patient Population – Patients with an MI at least one month prior to study entry and elevated hsCRP.
- Sponsor – Novartis
- Contact Information – (402) 384 – 2705, MPCHeartConsultantsResearch@nmhs.org
- View this study on ClinicalTrials.gov